Last reviewed · How we verify
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment
Details
| Lead sponsor | Yeon Hee Park |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 272 |
| Start date | Sun Feb 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Dec 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Breast Cancer Metastatic
Interventions
- Ribociclib with fulvestrant
- Physician's choice treatments group